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Abstract
Background: γδ T cells are important for both protective immunity and immunopathogenesis during malaria infection.
However, the immunological processes determining beneficial or detrimental effects on disease outcome remain elusive.
The aim of this study was to examine expression and regulatory effect of the inhibitory receptor T-cell immunoglobulin
domain and mucin domain 3 (TIM3) on γδ T cells. While TIM3 expression and function on conventional αβ T cells have
been clearly defined, the equivalent characterization on γδ T cells and associations with disease outcomes is limited. This
study investigated the functional capacity of TIM3+ γδ T cells and the underlying mechanisms contributing to TIM3
upregulation and established an association with malaria disease outcomes.
Methods: We analyzed TIM3 expression on γδ T cells in 132 children aged 5–10 years living in malaria endemic areas of
Papua New Guinea. TIM3 upregulation and effector functions of TIM3+ γδ T cells were assessed following in vitro
stimulation with parasite-infected erythrocytes, phosphoantigen and/or cytokines. Associations between the proportion of
TIM3-expressing cells and the molecular force of infection were tested using negative binomial regression and in a Cox
proportional hazards model for time to first clinical episode. Multivariable analyses to determine the association of TIM3
and IL-18 levels were conducted using general linear models. Malaria infection mouse models were utilized to
experimentally investigate the relationship between repeated exposure and TIM3 upregulation.
Results: This study demonstrates that even in the absence of an active malaria infection, children of malaria endemic
areas have an atypical population of TIM3-expressing γδ T cells (mean frequency TIM3+ of total γδ T cells 15.2% ± 12).
Crucial factors required for γδ T cell TIM3 upregulation include IL-12/IL-18, and plasma IL-18 was associated with TIM3
expression (P = 0.002). Additionally, we show a relationship between TIM3 expression and infection with distinct parasite
clones during repeated exposure. TIM3+ γδ T cells were functionally impaired and were associated with asymptomatic
malaria infection (hazard ratio 0.54, P = 0.032).
Conclusions: Collectively our data demonstrate a novel role for IL-12/IL-18 in shaping the innate immune response and
provide fundamental insight into aspects of γδ T cell immunoregulation. Furthermore, we show that TIM3 represents an
important γδ T cell regulatory component involved in minimizing malaria symptoms.
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Background
Immunoregulation is an essential part of the immune re-
sponse and ensures that a comprehensive and protective
response is elicited, but with limited damage to the host.
Immunoregulation can be achieved by check-point pro-
teins that either enhance or inhibit cell reactivity [1]. In-
appropriate expression of these proteins can therefore
have detrimental consequences for immune responses to
infection and also affect pathogenesis. Thus, blocking of
check-point proteins to restore functional capacity of ef-
fector cells has been explored as potential immunother-
apy for chronic viral infections and cancers [2–8]. The
expression of immunoregulatory proteins on conven-
tional T cells has been recently shown in both malaria
rodent infection models and in malaria-infected individ-
uals, where inhibitory therapies of immunoregulatory
proteins resulted in enhanced parasite clearance [9–13].
However, the effect of continuous malaria exposure on
immunoregulation among the innate cell compartment
remains a critically under-investigated aspect of malaria
immunology.
γδ T cells are a subset of T cells that express a distinct
T cell receptor (TCR). These cells are considered to be
part of the innate/intermediate immune system due to
their ability to respond rapidly to non-peptide antigens
without the requirement of major histocompatibility
complex (MHC) presentation. Substantial evidence indi-
cates that γδ T cells mediate essential protection against
a number of pathogens including Plasmodium [14–19]
where Plasmodium stimulation of γδ T cells involves
metabolites of the 1-deoxy-D-xylulose 5-phosphate
(DOXP) pathway [20]. While immunity to malaria re-
quires a multifaceted network of cell interactions and
cytokine production involving both innate and adaptive
immune responses, γδ T cells have been shown to con-
tribute to key processes associated with beneficial out-
comes [21, 22]. Mouse studies demonstrate that the
frequency of γδ T cells is significantly increased during
malaria infection and they provide protective immunity
via interferon gamma (IFN-γ) production and control of
parasitemia [21, 23, 24]. Similarly, γδ T cells are an im-
portant early source of IFN-γ in malaria-infected indi-
viduals, which is associated with reduced risk of clinical
disease [25–30]. Furthermore, inhibition of intracellular
parasite growth and granulysin-dependent cytotoxic ac-
tivity against released blood stage merozoites have been
demonstrated [14, 31–33]. However, in addition to a
protective role during malaria, γδ T cells were also sug-
gested to contribute to pathogenesis. This is supported
by observations that depletion of γδ T cells protected
mice from developing cerebral malaria in a P. berghei
ANKA mouse model [34] and that γδ T cells were found
to be one of the predominant sources of cytokines and
chemokines associated with severe malaria in malaria-
infected individuals [29]. Although numerous studies de-
scribe activation of γδ T cells in response to malaria, the
understanding of how these cells are regulated is re-
markably limited.
T-cell immunoglobulin domain and mucin domain 3
(TIM3) is a relatively recently described immunoregula-
tory protein that belongs to the TIM protein family. In
humans this family consists of TIM1, TIM3, and TIM4,
whereas mice have an additional protein, TIM2 [35–38].
TIM3 is expressed by T cells, dendritic cells (DCs), nat-
ural killer (NK) cells, and monocytes and interacts with
galectin-9 [39]. TIM3 is generally referred to as a nega-
tive regulator, but TIM3 expression can affect different
functions in the innate and the adaptive immune system
and on different cells. In mice, engagement of TIM3 on
conventional αβ T cells results in apoptosis and loss of
effector T cells [39], whereas TIM3 expression on hu-
man T cells is associated with functional exhaustion [4,
39–41]. In contrast, TIM3 is thought to be a maturation
marker on human NK cells [42] and is also abundantly
expressed on monocytes regulating cytokine production
in these cells [43, 44]. Recently TIM3 was observed to
be upregulated in mice during acute Plasmodium infec-
tion [13, 45]. TIM3 was found to be expressed by con-
ventional T cells and NK cells, and in vivo blocking of
TIM3 resulted in enhanced parasite clearance [13]. Fur-
thermore, TIM3-expressing CD4+ and CD8+ αβ T cells
were observed in individuals during acute P. vivax infec-
tion but were undetectable following treatment [46].
In contrast, the effect of TIM3 expression on γδ T cells
has only recently started to receive attention [47, 48]. In
malaria, the biological relevance of TIM3 expression on γδ
Tcell function for clinical outcomes has not previously been
investigated. Recent findings suggest that dysfunctional Vδ2
γδ T cells associated with malaria exposure induce tolerance
to the Plasmodium parasite [47]. However, the precise im-
munological processes responsible for γδ T cell dysregula-
tion remain elusive. Here, we specifically investigated
associations between TIM3 and γδ T cell function during
malaria as well as the factors that govern TIM3 upregula-
tion. The roles TIM3 expression plays in the control of
pathogenic mechanisms were also explored. Our main find-
ings revealed that interleukin (IL)-12 in synergy with IL-18
are key factors required for TIM3 induction. Moreover,
TIM3 expression renders cells functionally impaired, which
is associated with reduced risk of clinical malaria. These
findings provide novel insights into immune-specific pro-
cesses involved in γδ Tcell regulation and represent a major
advancement in the field of γδ Tcell biology.
Methods
Study site and subjects
Human blood samples from children aged 5–10 years were
collected in a clinical trial (ClinicalTrials.gov registration:
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NCT02143934) conducted in 2009 and 2010 in five villages
in East Sepik Province of Papua New Guinea (PNG), where
both P. falciparum and P. vivax are endemic [49]. Children
were randomized into two treatment groups of directly ob-
served treatment (DOT) over a total of 27 days. The first
group of children received chloroquine (CQ, days 1–3 of
DOT), artemether-lumefantrine (Coartem®) (AL, days 11–
13 of DOT), and primaquine (PQ, days 1–20 of DOT;
0.5 mg/kg per dose). The second group of children received
CQ (days 1–3 of DOT), AL (days 11–13 of DOT), and a
placebo (days 1–20 of DOT). The drug treatment was im-
plemented to be able to quantify the contribution of P.
vivax and P. ovale relapses to infection and disease during
follow-up in an epidemiological study of the cohort [49].
The first treatment regime was designed to clear all para-
sites including P. vivax hypnozoite stages, whereas the sec-
ond treatment regime cleared only blood stages. Venous
bleeds and peripheral blood mononuclear cell (PBMC) iso-
lation were performed following completion of drug treat-
ment, and PBMCs were cryopreserved.
Children were actively followed for 8 months with
finger-prick (250-μl) blood samples collected every
2 weeks for the first 12 weeks and every 4 weeks for the
remainder of the follow-up period. In addition passive
surveillance measures were implemented at local health
centers, aid posts, and via the village health volunteer
network. Febrile children were tested with a rapid diag-
nostic test (RDT), and a blood slide was collected.
Symptomatic infections (those with fever and who tested
positive by RDT and/or light microscopy) during follow-
up were treated with AL. For RDT-negative children, the
slides were read within 12 h. If the slides were positive,
the children were treated the next day. If the slide was
negative, the result was recorded but no further action
taken. The collected blood samples were screened for in-
fection with Plasmodium spp. by light microscopy and
quantitative real-time PCR (qPCR). Slides were scored as
light microscopy-positive for an individual Plasmodium
species if the species was detected independently by at
least two microscopists and/or if subsequent qPCR diag-
nosis confirmed the presence of the species. Slide discrep-
ancies were adjudicated by a World Health Organization
(WHO)-certified level 1 (expert) microscopist [49]. A gen-
eric qPCR was used to detect all Plasmodium species oc-
curring in PNG, followed by subsequent species-specific
qPCRs on Plasmodium-positive samples [50, 51].
A subset of PBMC samples from the children enrolled
in the clinical trial (n = 132, of which n = 63 belonged to
the primaquine drug-treated group and n = 69 belonged
to the placebo group) were included in the current study.
These children all had at least one Plasmodium falcip-
arum infection verified by PCR during follow-up to ensure
ongoing exposure. Of these, 50 individuals had a clinical
episode during follow-up. A clinical episode of malaria
was defined as febrile illness (axillary temperature of
≥37.5 °C, current or previous 48 h) plus the presence of P.
vivax or P. falciparum parasites (any density) by light mi-
croscopy. PBMCs collected from 20 healthy blood donors
by the Australian Red Cross were used as controls.
Mouse infections
Female C57BL/6 mice aged 6–8 weeks were infected with
5 × 104 Plasmodium chabaudi-infected red blood cells
(iRBCs) intravenously or with 1 × 106 P. berghei ANKA
iRBCs intraperitoneally. P. chabaudi-infected mice were
drug-treated on day 14 post-infection with CQ (6 μg/ml)-
and pyrimethamine (70 μg/ml)-containing water for 5 days.
Drug treatment on day 14 coincided with control of the in-
fection and allowed for a whole infection cycle to be com-
pleted before drug treatment. P. berghei-infected mice were
treated at day 5 post-infection to avoid progression to cere-
bral malaria. Drug treatment consisted of an intraperitoneal
injection of CQ (10 mg/kg) and pyrimethamine (10 mg/kg)
followed by CQ- and pyrimethamine-containing water for
5 days as described previously [52]. Livers and spleens were
removed at different time points following completion of
drug treatment. Untreated P. chabaudi-infected mice estab-
lish a submicroscopic chronic infection with intermittent
detectable parasitemia peaks. Mice that were chronically in-
fected with P. chabaudi were left untreated until day 98
after the initial infection. Mice infected multiple times
(three consecutive infections (P. chabaudi only) or two
consecutive infections (P. chabaudi and P. berghei)) were
drug-treated and then re-infected on day 14 post-
completion of drug treatment to allow the immune cells to
return to steady state (Additional file 1: Figure S1).
Parasite lines and cultures
Parasite lines 3D7 and XIE were cultured in human red
blood cells, and trophozoite-stage parasites were isolated
as described previously [29, 53]. XIE parasites were snap
frozen in 15% glycerol in phosphate-buffered saline
(PBS) and thawed by sequential addition of 12%, 1.8%,
and 0.9% NaCl and subsequently used for stimulation of
cohort samples.
Flow cytometry
PBMCs (5 × 105) were stained with antibody cocktails
in FACS buffer (PBS containing 0.5% bovine serum
albumin and 2 mM ethylenediaminetetraacetic acid)
on ice for 30 min. The human antibodies used were
fluorescein isothiocyanate (FITC)-conjugated anti-γδTCR
(clone 11 F2, BD Biosciences, San Jose, CA, USA), Qdot
605-conjugated anti-CD27-, Qdot 655-conjugated Strepta-
vidin (Invitrogen, Carlsbad, CA, USA), PE-Texas Red
(ECD)-conjugated anti-CD3 (clone UCHT1, Beckman
Coulter, Brea, CA, USA), Brilliant Violet 421-conjugated
anti-CD16-(clone 3G8), Brilliant Violet 711-conjugated
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anti-CD45RA (clone HI100, both from Biolegend, San
Diego, CA, USA), and phycoerythrin (PE)-conjugated anti-
TIM3 (clone FAB2365P from R&D Systems Minneapolis,
MN, USA). The mouse antibodies used were FITC-
comjugated anti-CD3 (clone 145-2C11), PE-conjugated
anti-TIM3 (clone RMT3-23), and PerCPCy5.5-conjugated
anti-γδTCR (clone GL3, all from Biolegend). Aqua amine
reactive dye (Invitrogen) was used for dead cell exclusion.
Samples were analyzed on a four-laser Fortessa flow cyt-
ometer (BD Biosciences). Data analysis was performed
using FlowJo software (Tree Star, Ashland, OR, USA).
Boolean gating was utilized to evaluate multiparametric
expression, and fluorescence minus one (FMO) con-
trols were used to set gates. The gating strategy is illus-
trated in Additional file 2: Figure S2.
Intracellular cytokine staining
PBMCs (2 × 105 cells/well in triplicate) were stimulated
with either uninfected RBCs (uRBCs) or iRBCs (6 × 105/
well) for 24 h or isopentenyl pyrophosphate (IPP, 3 μM,
Sigma-Aldrich, St Louis, MO, USA) for 16 h. Brefeldin
A (10 μg/ml, Sigma-Aldrich) and monensin (BD Biosci-
ences) were added to the cells for the last 8 h of incuba-
tion. Assessment of γδ T cell cytokine production was
performed by intracellular cytokine staining using allo-
phycocyanin (APC)-conjugated anti-IFN-γ (clone B27,
BD Biosciences) and PE-Cy7-conjugated anti-tumor ne-
crosis factor alpha (TNF-α) (clone MAb11, eBioscience,
San Diego, CA, USA), and cytotoxic capacity was
assessed by Brilliant Violet 421-conjugated anti-CD107a
(clone H4A3, Biolegend) staining in culture. A positive
response was determined as the frequency of responding
cells, which was twice above background and was ≥0.1%
IFN-γ, TNF-α, or CD107a-positive γδ T cells of all γδ T
cells or ≥0.5% positive γδ T cells of γδ T cell subsets fol-
lowing subtraction of background.
Cytokine and antigen stimulation of PBMCs
PBMCs (5 × 105 cells) from healthy individuals were
stimulated with the following conditions: IL-6 (10 ng/
ml), IFN-γ (10 ng/ml), IL-12/IL-18 (50 ng/ml each), IL-4
(10 ng/ml), IL-1β (1 ng/ml, all from Peprotech, NJ),
TNF-α (10 ng/ml, Life Technologies, Carlsbad, CA,
USA), iRBCs (3 iRBCs: 1 PBMC), lipopolysaccharide
(LPS, 1 ug/ml, InvivoGen, San Diego, CA, USA), IPP
(3 μM), or cells in medium only. After 24 h of incuba-
tion, the frequency of TIM3+ γδ T cells was assessed by
flow cytometry.
Enzyme-linked immunosorbent assay (ELISA)
Plasma was assessed for IL-12p70 and IL-18 cytokine
levels using ELISA (RayBiotech, Norcross, GA, USA) ac-
cording to the manufacturer’s instructions. Plasma from
healthy controls were included as negative controls for
IL-12 and to measure the baseline plasma IL-18 concen-
tration of healthy individuals.
Statistical analysis
Statistical analyses were performed using Prism 6.0
(GraphPad software) and STATA 12. Flow cytometry
data were analyzed using the Student’s t test or Kruskal-
Wallis test followed by the Dunn post-test as indicated.
Correlation coefficients were determined by Spearman
rank correlation. Logistic regression was used to test
whether recent infection was associated with an in-
creased proportion of TIM3+ γδ T cells and whether
TIM3 expression varied the odds of experiencing a clin-
ical malaria episode during the follow-up period. Associ-
ations between molecular force of infection (molFOI) and
the proportion of TIM3-expressing cells were tested
using negative binomial regression and in a Cox propor-
tional hazards model for time to first clinical episode. In
order to normalize the TIM3 expression levels, the data
were power transformed. Clinical incidence was defined
as the frequency of occurrence per time at risk of infec-
tions associated with a fever. molFOI was determined by
genotyping all samples for merozoite surface protein 2
(msp2) using capillary electrophoresis for fragment siz-
ing [54, 55] in addition to using PCR conditions for
highly purified DNA [56]. molFOI was defined as the fre-
quency of acquisition of new malaria infections per time
at risk [55]. New infections were defined as those where
the detected allele had not been observed in a child at the
previous two active or passive case detection visits [49].
Time at risk was adjusted for missed visits, and children
were censored from the analysis after they missed three or
more active case detection visits. Multivariable analyses to
determine the association of TIM3 levels and relevant co-
variates, including IL-18 levels, were conducted using gen-
eral linear models (GLMs). Backwards elimination was
applied to construct the most parsimonious model.
Results
TIM3 expression is upregulated on γδ T cells following
acute infection
TIM3 expression is present on the surface of activated
αβ T cells following stimulation and acts as a negative
regulator [4, 39–41]. Recently TIM3 expression on con-
ventional T cells was demonstrated to be upregulated
during acute Plasmodium infection in both mice and
humans [13, 46]. In contrast, little is known about TIM3
expression on γδ T cells and whether Plasmodium infec-
tion is associated with γδ T cell TIM3 expression. It is
also not established whether TIM3+ γδ T cells remain
detectable even in the absence of an active infection or
whether chronic infection is required. Prolonged expres-
sion of negative regulators such as TIM3 may affect re-
sponses to subsequent infections. This may be especially
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important in settings where an individual is rep-
eatedly infected with a pathogen, such as in malaria
endemic areas. To address these questions, we exam-
ined TIM3 expression on γδ T cells following acute
malaria infection. To that end, C57BL/6 mice were
infected with P. chabaudi iRBCs, and 14 days post-
infection, mice were drug-treated to resolve infection
completely. Cells were isolated from the liver and
spleen at different time points (0–14 days) following
completion of drug treatment, and γδ T cells were
subsequently assessed for TIM3 expression (Fig. 1a
and b). We found that the frequency of TIM3+ γδ T
cells was significantly increased in both liver (mean
9.69 ± 1.01) and spleen (mean 36.9 ± 5.66) immediately
following resolution of acute infection compared to
naive mice (liver: 2.66 ± 1.25 and spleen: 2.84 ± 0.45).
The presence of these cells remained significantly in-
creased in the spleen for up to 14 days (mean 3.61 ±
0.33, Fig. 1b), whereas TIM3 expression by hepatic γδ
T cells returned back to background levels by day 3
post-completion of drug treatment (mean 1.77 ± 0.53,
Fig. 1a). Similarly, the total number of TIM3+ γδ T
cells in the spleen significantly increased from day 0
after drug treatment (mean 9.5 × 105 ± 2.7 × 105 cells,
Fig. 1d) compared to naive mice (mean 1.8 × 104 ±
6.3 × 103 cells) and remained significantly increased
until the last measured time point at day 14. How-
ever, the total number of all γδ T cells in the spleen
at day 0 was not significantly different from that of
naive mice (Fig. 1f ). In contrast, the number of TIM3+
γδ T cells and the total number of all γδ T cells in the liver
were not significantly increased compared to naive mice,
apart from day 3 when a small increase in the number of
TIM3+ γδ T cells was observed (Fig. 1c and e). To deter-
mine whether a TIM3+ γδ T cell population was persist-
ently detectable in untreated, chronically P. chabaudi-
infected mice, γδ T cells from these mice were assessed on
day 98 p.i (Fig. 1g and h). We found that TIM3+ γδ T cells
were present in both liver and spleen at a significantly
higher frequency compared to naive mice (P = 0.0002 and
P = 0.0006 respectively). An outlier, which had a high fre-
quency of TIM3+ γδ T cells in both organs, was ob-
served. Although at the time of analysis parasitemia
was submicroscopic in this mouse, a recent recur-
rence of parasitemia is likely to have occurred. The
difference in frequency of TIM3+ γδ T cells between
the remaining chronically infected mice compared to
naive mice remained significant when the outlier was
excluded from the analysis (P = 0.0003 and P = 0.0012
respectively). This demonstrates that acute malaria in-
fection induces γδ T cell TIM3 expression, and a
population of TIM3+ γδ T cells is continually detect-
able both during chronic infection and following reso-
lution of infection.
The frequency of TIM3+ γδ T cells is increased in children
living in malaria endemic areas
TIM3 expression is commonly absent on γδ T cells dur-
ing steady state. However, we show that TIM3 expres-
sion is induced in Plasmodium-infected mice. To extend
these observations to human malaria, TIM3 expression
was examined on γδ T cells from PBMC isolated from
drug-treated children residing in malaria endemic areas
in PNG (n = 132). We found that despite the absence of
active malaria infection, all PNG children exhibited sig-
nificantly higher proportions of TIM3+ γδ T cells com-
pared to healthy controls (HC) (Fig. 2a). In addition,
children who had experienced a recent infection at en-
rollment (28–30 days prior to PBMC collection) had a
significantly increased frequency of TIM3-expressing γδ
T cells compared to children who were malaria free at
enrollment (P ≤ 0.001). In contrast, no expression of
PD1 was observed on γδ T cells, but it was expressed at
low frequencies on CD3+ γδTCR– cells (Additional file
3: Figure S3). This indicates that malaria exposure in-
duces TIM3 expression, which is maintained for a con-
siderable duration even in the absence of new infections.
To assess whether the infective Plasmodium species
affected TIM3 expression, we compared the frequency
of TIM3+ γδ T cells between children who were infected
with P. vivax or P. falciparum at enrollment or had a
co-infection of P. vivax, P falciparum, P. ovale, or P.
malariae with a minimum of two species present. We
found that TIM3+ γδ T cell was significantly increased
in children with either P. falciparum single infections
(P ≤ 0.05) or co-infections (P ≤ 0.01) compared to P.
vivax infections alone (Fig. 2b). This suggests that infec-
tions with different species result in dissimilar TIM3 ex-
pression profiles.
γδ T cells are present in the periphery in a “pre-acti-
vated” state and can be divided into subsets based on ex-
pression of surface markers CD27 and CD45RA [57–60].
To assess which subsets of γδ T cells expressed TIM3, we
distinguished between naive (CD27+ CD45RA+), central
memory (TCM; CD27+CD45RA–), effector memory
(TEM; CD27– CD45RA–), and terminally differentiated
effector memory (TEMRA; CD27– CD45RA+) γδ T cells
(Fig. 2c, Additional file 2: Figure S2). We found that TIM3
was predominantly expressed on TEMRA γδ T cells. A
subset of TEMRA cells have previously been found to ex-
press the low affinity FC receptor CD16 which defines a
functionally discrete effector population, with high cyto-
kine and cytotoxic capacity [61]. To determine the extent
of TIM3 and CD16 co-expression, additional phenotypic
analysis of the TEMRA subset was performed. We found
that the majority of TIM3 expression was present on
CD16+ TEMRA γδ Tcells (Fig. 2d, Additional file 2: Figure
S2). This demonstrates that TIM3 is primarily expressed
by a memory γδ Tcell population with specific function.
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γδ T cell TIM3 expression is associated with exposure to
distinct parasite species and clones
We have shown that TIM3 expression differs in children
infected with different Plasmodium species (Fig. 2b). To
better understand the relationship between malaria ex-
posure and TIM3 expression levels, the incidence of
new clones acquired by each child during the follow-up
period (molFOI) was tested for association with TIM3.
We found that expression levels on CD16+ TEMRA γδ
T cells specifically were found to be significantly as-
sociated with molFOI for P. falciparum (Table 1 and
Additional file 4: Table S1, adjusted incidence rate ratio
(IRR): 1.40, 95% confidence interval (CI): 1.04–1.88, P =
0.027), for each increment of power transformed TIM3
expression after adjusting for potential confounders: age,
sex, treatment arm, infection status at enrollment, and
hemoglobin level. No significant association was found
with molFOI for P. vivax. This suggests that in endemic
areas, exposure to diverse parasites is a contributing fac-
tor for TIM3 upregulation in innate cells.
To test the effect of consecutive infections with the
same Plasmodium species or different species on TIM3
expression experimentally, a mouse infection model was
used where C57BL/6 mice were repeatedly infected with
P. chabaudi or P. berghei with drug treatment between in-
fections. Livers and spleens were removed on day 7 after
Fig. 1 TIM3 expression is maintained on γδ T cells after drug treatment and parasite clearance. C57BL/6 mice were infected with P. chabaudi and then
drug-treated with chloroquine and pyrimethamine. (a) Liver lymphocytes and (b) splenocytes were stained for TIM3 expression at different time points
following end of drug cure to assess the percentage of TIM3+ γδ T cells, (c) and (d) number of TIM3+ γδ T cells, and (e) and (f) the total number of γδ T
cells in the liver and spleen. The data represent three mice per time point and shows mean ± standard deviation (SD). Chronically P. chabaudi-infected mice
(n= 8) were assessed on day 98 post-infection for TIM3+ γδ T cells in the (g) liver and (h) spleen. The data represent two independent experiments.
Statistical analysis was performed using (a-f) paired t tests with Holm-Sidak method or (g) and (h) Student’s t test. *P< 0.05, **P< 0.01, ***P< 0.001
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completion of the final round of drug treatment and
assessed for TIM3+ γδ T cells (Additional file 1: Figure
S1A). We found that mice repeatedly infected (three infec-
tions) with the same species (multiple P. chabaudi) did
not have an increased frequency of TIM3+ γδ T cells in
the spleen or in the liver (Fig. 3a and b) compared to
naive mice. Control groups of mice received a single infec-
tion of P. chabaudi and were either drug-treated on day 14
(P. chabaudi day 7) or day 98 post-infection (P. chabaudi
day 98, Additional file 1: Figure S1C) and then assessed for
TIM3+ γδ T cells 7 days post-drug treatment. Consistent
with Fig. 1a and b, TIM3+ γδ T cells were observed in the
spleens of P. chabaudi day 7 mice, but not in the liver. To
investigate if multiple infections with different species had
an effect on TIM3 expression, we infected mice with P.
chabaudi followed by drug treatment and then P. berghei
infection (P. chabaudi + P. berghei) or vice versa (P. berghei
+ P. chabaudi) (Additional file 1: Figure S1B and Fig. 3c
and d). In contrast to mice exposed multiple times to a sin-
gle malaria species, mice infected sequentially with different
species had an increased proportion of TIM3+ γδ T cells in
both the spleen and liver compared to naive mice (P ≤ 0.05
and P ≤ 0.05 respectively). TIM3+ γδ T cells were also ob-
served following a single infection of P. berghei at day 7
post-drug treatment completion. Collectively, these obser-
vations show that TIM3 is induced following a single infec-
tion, but not by sequential infections with the same species
and clones. However, consecutive infections with different
species or different clones from the same species (as indi-
cated in Table 1) contribute to TIM3 expression in innate
cells during repeated exposures.
TIM3+ γδ T cells are dysfunctional and are associated
with lower risk of acquiring clinical episodes
To investigate the relationship between expression of
TIM3 and cytokine and cytotoxic capacity, the functional
Fig. 2 γδ T cell TIM3 expression in individuals from malaria endemic areas is increased compared to healthy controls (HC). PBMCs from individuals
living in malaria endemic areas recently infected in the last 30 days, not recently infected, and healthy controls (HC) were surface stained for TIM3
expression. a Frequency of γδ T cells expressing TIM3 (recently infected, filled triangles, n = 92; not recently infected, open circles, n = 40; and healthy
controls, filled circles, n = 20). b Percentage of γδ T cells expressing TIM3 in individuals recently infected with either P. vivax only (filled circles; n = 32), P.
falciparum only (filled squares; n = 13), or co-infected with multiple species (P. vivax, P. falciparum, P. ovale, and P. malariae) (filled triangles; n = 47). c
Frequency of TIM3+ γδ T cell subsets distinguished by expression of CD27 and CD45RA (TCM central memory T cell, TEM effector memory T cell, TEMRA
terminally differentiated effector memory T cell). d Frequency of TIM3-expressing CD16+ (open circles) and CD16– (squares) TEMRA γδ T cells (mean ± SD).
Statistical analysis was performed using (a–c) Kruskal-Wallis tests with Dunn’s post-test; cmultiple comparison to naive, and (d) paired Student’s t tests.*P<
0.05, **P< 0.01, ***P< 0.001
Table 1 The most parsimonius model for negative binomial regression for TIM3+ CD16+ TEMRA γδ T cell frequency and molFOI
P. falciparum force of infection IRR P 95% CI
PQ treatment arm 0.74 0.035 0.57 0.98
% TIM3+ CD16+ TEMRA γδ T cell (power transformed) 1.40 0.027 1.04 1.88
Hb at sampling 0.85 <0.001 0.77 0.93
Recent P. falciparum (P. falciparum infection at enrollment) 1.85 <0.001 1.39 2.46
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capacity of TIM3+ γδ T cells was determined in a sub-
set of children where cells were available. Cytokine pro-
duction and cytotoxic activity was assessed following
stimulation with iRBCs or the phosphoantigen isopen-
tenyl pyrophosphate (IPP). The predominant subsets
that produce either IFN-γ or TNF-α following these
stimulation conditions were TCM and TEM, collect-
ively here referred to as memory γδ T cells, whereas
cytotoxic activity was mainly observed in TEM and
TEMRA subsets. The overall magnitude of the re-
sponses of all γδ T cells following background subtrac-
tion is summarized in Additional file 5: Table S2.
Children were divided into responders and non-
responders. A positive response was determined as cyto-
kine production and cytotoxic activity following stimula-
tion, which was twice above background and with a
frequency of ≥0.1% positive γδ T cells of all γδ T cells or
≥0.5% positive γδ T cells of γδ T cell subsets following
subtraction of background. Representative FACS plots of
responses are presented in Additional file 6: Figure S4.
We found that children in which γδ T cells did not pro-
duce cytokine (non-responders, n = 30) or lacked cyto-
toxic activity (n = 33) following stimulation with iRBCs
had a significantly higher proportion of TIM3+ γδ T cells
compared to individuals where γδ T cells responded to
antigenic stimuli (Fig. 4a and b; cytokine responders n =
21, P = 0.0005 and CD107a responders n = 31, P = 0.015).
Comparable results were observed with cytokine produc-
tion following IPP stimulation, but not with cytolytic γδ T
cells (Fig. 4e and f). Further analysis assessing TIM3
expression of all IFN-γ+, TNF-α+, and CD107a+ γδ T cells
following stimulation with iRBCs (Fig. 4c and d) or IPP
(Fig. 4g and h) revealed that effectively all cells that pro-
duce cytokines and exerted cytotoxic activity do not ex-
press TIM3 (Additional file 6: Figure S4). Collectively, this
demonstrates that TIM3+ γδ T cells do not produce IFN-
γ or TNF-α and lack cytotoxic activity in response to iRBC
or phosphoantigen. Thus, the presence of these cells in
the periphery of individuals may significantly affect their
ability to respond to pathogens.
To further understand the relevance of these processes
for the development of symptomatic malaria, associa-
tions between TIM3 expression on γδ T cells and the oc-
currence and incidence of clinical malaria during the
follow-up period were explored. Significantly higher fre-
quencies of CD16+ TIM3+ TEMRA γδ T cells were
found in individuals who only experienced an asymp-
tomatic infection (n = 70) compared to children who had
at least one clinical episode (Fig. 5, n = 50, P = 0.022). In
addition in a proportional hazards model adjusting for
Fig. 3 Infection and exposure to multiple malaria species are associated with upregulated TIM3 expression. C57BL/6 mice were infected with P.
chabaudi and then drug-treated with chloroquine and pyrimethamine. (a) Liver lymphocytes and (b) splenocytes were stained for TIM3 expres-
sion on day 7 following completion of drug cure to assess the percentage of TIM3+ γδ T cells from mice which received either three sequential
P. chabaudi infections (Multiple P. chabaudi, n = 5), single P. chabaudi infection (P. chabaudi Day 7, n = 9), or single P. chabaudi infection 98 days
prior to assessment (P. chabaudi Day 98, n = 3). C57BL/6 mice were infected with either P. chabaudi or P. berghei and then drug-treated. (c) Liver
lymphocytes and (d) splenocytes were assessed for TIM3+ γδ T cells on day 7 following end of drug cure from mice which received either P. cha-
baudi infection followed by P. berghei infection (P. chabaudi + P. berghei, n = 8), P. berghei infection followed by P. chabaudi infection (P. berghei +
P. chabaudi, n = 9), or single P. berghei infection (P. berghei Day 7, n = 5). The data represent two independent experiments. Statistical analysis was
performed using Kruskal-Wallis tests with Dunn’s post-test; comparison to naive mice. *P < 0.05, **P < 0.01, ***P < 0.001
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other covariates, the frequency of the CD16+ TIM3+
TEMRA γδ T cells was also associated with a longer
time to first clinical episode (Table 2 and Additional file
7: Table S3, hazard ratio: 0.54, 95% CI: 0.30–0.95, P =
0.032). Together these results indicate that the presence
of CD16+ TIM3+ TEMRA γδ T cells is a predictor of fa-
vorable disease outcome.
TIM3 expression by γδ T cells is induced by pro-
inflammatory cytokines and phosphoantigens
During Plasmodium infection a range of cytokines are in-
duced which are associated with both protective responses
as well as clinical outcomes and are also important for ei-
ther a Th1 or Th2 response [62]. To determine if parasite-
specific stimuli or specific cytokines related to malaria
Fig. 4 TIM3+ γδ T cells are functionally inactive following stimulation with iRBCs and IPP. PBMCs from individuals living in malaria endemic areas
were stimulated with iRBCs and then surface stained for TIM3 expression. Frequency of TIM3+ γδ T cells in (a) and (e) cytokine responders and
non-responders and (b) and (f) in individuals with or without cytotoxically active γδ T cells after stimulation with iRBC or IPP (responders; filled
squares and non-responders; open circles). Comparison of TIM3 expression by (c) and (g) cytokine-producing γδ T cells and (d) and (h) cytotoxic
γδ T cells (TIM3+; filled circles and TIM3–; filled squares) in iRBC- or IPP-responding individuals. Statistical analysis was performed using (a, b, e, and
f) Mann-Whitney tests and (c, d, g, and h) Wilcoxon matched pairs signed-rank test. *P < 0.05, **P < 0.01, ***P < 0.001
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infection induce TIM3 expression on γδ T cells, we stimu-
lated PBMCs from healthy individuals in vitro with cyto-
kines (IL-6, IL-1β, TNF-α, IL-12/IL-18, IL-4, and IFN-γ),
IPP, iRBCs, or LPS for 24 h. TIM3 was detected on the
surface of γδ T cells only in the presence of IPP and IL-
12/18 (Fig. 6a). Furthermore, IL-18 alone was unable to
upregulate TIM3, but it augmented IL-12-induced TIM3
expression (Fig. 6b). As only IL-12/IL-18 induced TIM3
expression on γδ T cells, the plasma levels of these TIM3-
inducing cytokines were investigated in the PNG children.
Interestingly, plasma IL-18 levels were correlated with
TIM3 expression (Fig. 6c; r = 0.30, P = 0.0005). This
correlation remained significant in recently P. falciparum-
infected children (Fig. 6d; r = 0.44, P = 0.0009) and in mul-
tivariable analyses (Table 3 and Additional file 8: Table S4,
coefficient 0.03, 95% CI: 0.009–0.04, P = 0.002), whereas
this association was not observed in non-P. falciparum-in-
fected children (Fig. 6e; r = 0.096, P = 0.41), suggesting that
IL-18 levels are driven by P. falciparum infection. In con-
trast, plasma IL-12 levels were undetectable in the major-
ity of children at this time point.
Discussion
The significant contribution of γδ T cells to the overall
immunity during infection and cancer is increasingly ap-
preciated. Although recent efforts to utilize γδ T cells as
immunotherapy effector cells have produced promising
results [63], it is evident that a more comprehensive
understanding of the biology related to immunoregula-
tion of these cells is required to overcome the demon-
strated induction of anergy and exhaustion upon repeat
exposure to antigens [64, 65]. Our data demonstrated
that in an infectious disease setting with continuous ex-
posure to malaria, TIM3 expression becomes upregu-
lated on γδ T cells, and this process is controlled by
environmental cues provided by the host immune re-
sponse. IFN-γ, TNF-α, and cytotoxic activity were found
to be absent in TIM3+ γδ T cells upon re-stimulation
with malaria antigens, and increased frequencies of these
cells were associated with reduced risk of clinical
malaria.
Although P. vivax is considered less virulent than P.
falciparum, P. vivax is still a major cause of morbidity in
endemic areas. Nevertheless, substantial differences in
immunity to the two species have been noted, in par-
ticular in regard to naturally acquired immunity, where
immunity to P. falciparum is slower to develop than im-
munity to P. vivax [66]. Few studies have compared in-
nate responses and cytokine profiles between these
species, though dissimilarities are plausible considering
the distinct naturally acquired immunity patterns. We
observed that recent infection with either P. vivax or P.
falciparum affected the frequency of TIM3+ γδ T cells.
However, the extent of TIM3 upregulation was different
depending on the infective species. CD4+ T cells upregu-
late TIM3 following extended stimulation with IL-12
[67]. Similarly, we also found that IL-12/IL-18 can pro-
mote γδ T cell upregulation of TIM3 in vitro where IL-
18 plays an auxiliary role. While both Plasmodium spe-
cies are associated with increases in IL-12 production
during acute infection, P. falciparum infection has been
demonstrated to result in higher plasma IL-12 levels
during convalescence [68, 69]. In the current cohort IL-
12 was undetectable in the plasma, which is likely due to
the absence of active infection for 28–30 days preceding
the time point for PBMC collection. However, IL-18
plasma levels were readily detectable and were associ-
ated with TIM3 expression in P. falciparum-infected
children at enrollment. Thus, dissimilar cytokine profiles
and concentration levels at the time of infection may
contribute to the difference in TIM3+ γδ T cell frequen-
cies observed between children recently infected with P.
vivax and P. falciparum. Notably, IL-12/IL-18 can also
induce IFN-γ production by γδ T cells. However, the ef-
fect of IL-12/IL-18 on TIM3 induction by γδ T cells may
be dose-dependent, as was previously shown for TIM3
expression on CD4+ T cells [67]. Thus, early production
of IL-12/IL-18 may promote IFN-γ production, whereas
accumulation of these cytokines in the plasma may in-
duce γδ T cells to upregulate TIM3. Furthermore, while
no association was observed between IL-18 plasma levels
in children who were not infected with P. falciparum
Fig. 5 Children who experience a clinical episode during follow-up have
decreased frequency of TIM3+ CD16+ TEMRA γδ T cells. Frequency of
TIM3+ CD16+ TEMRA γδ T cells in children with a clinical episode (filled
circles; n= 50) versus children with asymptomatic infection (open circles;
n= 72) during follow-up. Statistical analysis was performed using
Mann-Whitney tests. *P< 0.05
Table 2 The most parsimonius model for proportional hazard
model for TIM3+ CD16+ TEMRA γδ T cell frequency and time to
first clinical malaria episode
Hazard ratio P > z 95% CI
TIM3+ CD16+ TEMRA γδ T cells 0.54 0.032 0.30 0.95
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and TIM3 expression, these children still have an in-
creased population of TIM3+ γδ T cells. It is possible
that phosphoantigen contributes to the observed TIM3
expression in these children, as IPP was also observed to
induce TIM3 expression, albeit at lower frequency. How-
ever this remains to be determined.
Experimental mice infected with different Plasmodium
species resulted in significant TIM3 upregulation, and
TIM3+ γδ T cells remained detectable after resolution of
infection. Comparable findings were observed in the
PNG children where TIM3 expression was associated
with molFOI, thus suggesting that exposure to distinct
parasites is important for induction of TIM3 during re-
peated exposure. Cytokine responses to malaria have
been reported to be influenced by the immune status of
the host [70, 71]. It is possible that the differences in
cytokine profiles resulting from re-infection with the
same parasite among immune hosts versus infection
with a new clone or species may affect TIM3 expression
in the innate cell compartment.
Continuous exposure to malaria is correlated with im-
munity to symptomatic disease and is likely to involve
both antiparasitic mechanisms and regulation of cytokines
implicated in immunopathogenesis [72]. γδ T cells play a
protective role as a major IFN-γ producer during malaria
infection [73] but are also a major source of cytokines and
chemokines associated with disease [29]. Typically, Vγ9+
Vδ2+ T cells are considered to be the malaria-antigen re-
sponsive cells and also represent the majority of γδ T cells
in peripheral blood [31, 74]. However, the functional roles
for γδ T cells in general are continuously expanding, indi-
cating that the contribution of other subsets of γδ T cells
to both malaria immunity and immunopathogenesis may
not be completely appreciated. Therefore, in contrast with
the previous studies, we investigated TIM3 expression on
the total γδ T cell population without distinguishing sub-
sets based on TCR restriction. In the current study, we
found that the TIM3+ γδ T cells from malaria-exposed in-
dividuals were effectively unresponsive to stimulation in
vitro. The cells produced minimal IFN-γ and TNF-α and
demonstrated low cytotoxic activity in response to iRBCs
or phosphoantigen, thus indicating that these cells were
functionally impaired. Interestingly, we observed that
TIM3 was predominately expressed by CD16+ TEMRA
γδ T cells. Our study is aligned with recent findings
suggesting that dysfunctional CD16+ γδ T cells emerge in
Fig. 6 TIM3 is upregulated by IL-12/18 and IPP. PBMCs from healthy individuals (n = 10) were stimulated with (a) iRBCs (3:1), LPS, IPP, or cytokines
(IL-6, IFN-γ, TNF-α, IL-12/IL-18, IL-4, IL-1β) or (b) IL-12 and IL-18 for 24 h and then surface stained for TIM3 expression. The frequency of γδ T cells
expressing TIM3 was compared to that of unstimulated cells. Correlation of IL-18 plasma levels and TIM3 expression in (c) all children (n = 132),
(d) children with P. falciparum infection at enrollment (n = 55), and (e) children with no P. falciparum infection at enrollment (n = 77). Statistical
analysis was performed using Kruskal-Wallis tests with Dunn’s post-test (a and b) and Spearman rank correlation (c and d). **P < 0.01, ***P < 0.001
Table 3 The most parsimonius model for general linear model
of TIM3+ γδ T cell frequency with IL-18 levels in children with
recent P. falciparum infection
Coefficient P 95% CI
IL-18 (μg/ml) 0.03 0.002 0.009 0.04
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response to malaria exposure [75]. While CD16 upregula-
tion is most likely a consequence of prior TCR activation
[76], expression of CD16 alone does not explain why these
cells are impaired. Here we identified TIM3 as a potential
receptor responsible for the γδ T cell impairment associ-
ated with malaria infection.
It is worth noting that the CD16+ TEMRA γδ T cell
subset is reported to be unresponsive to phosphoantigen
stimulation [61]. Instead CD16 allows γδ T cells to
recognize opsonized targets. Farrington et al. (2016) pro-
posed that accumulation of CD16+ cells represents a
population which is preferentially stimulated through
this receptor independently of the TCR [75]. However,
signaling through CD16 results in both TNF-α and IFN-
γ production [61, 76]. Given that TNF-α is a pyrogenic
cytokine that significantly contributes towards malaria
febrile disease [77, 78], it indicates that inhibition of
CD16+ TEMRA γδ T cells may be necessary to limit
immunopathogenesis in the host. Notably, this study
identifies specifically that the TIM3+ CD16+ TEMRA γδ
T cell population was associated with reduced clinical in-
cidence risk, which supports the concept that regulation
of highly specialized subsets is important for reducing
clinical malaria symptoms. Thus, increased TIM3 ex-
pression on this population was associated with less risk
of febrile malaria and was associated with asymptomatic
infections. While TIM3 may not directly inhibit CD16
signaling, a functional linkage between CD16 and TCR
signaling has been reported [79]. In αβ T cells, TIM3 in-
hibition of TCR signaling is regulated by Bat3 inter-
action potentially through binding of catalytically active
Lck [80]. Thus, TIM3 inhibition of the TCR may also
affect the CD16-dependent response in this γδ T cell
population, although this remains to be determined.
While we detected TIM3+ γδ T cells in the mouse
model, in vivo assessment of their relative contribution to
disease outcome using either a TIM3 knock-out mouse
model or TIM3 depletion or blocking is hampered by the
fact that TIM3 is known to be expressed by several differ-
ent cell populations. These approaches would result in the
inability to specifically assign effects on disease outcome
to TIM3+ γδ Tcells. Thus, a conditional knock-out mouse
model would be required to address this. Furthermore,
adoptive transfer of TIM3+ γδ T cells is potentially con-
founded by the presence of bound antibody, which may
interfere with endogenous ligand interaction. Conse-
quently, experimentally defining the role of TIM3+ γδ T
cells for malaria disease outcome in vivo still remains
unresolved.
Conclusions
In conclusion, this study demonstrates the effect of
continuous malaria exposure in shaping the innate
immune response. The findings further emphasize the
importance of regulating immune cells as part of clinical
immunity to malaria. However, they also demonstrate
that the inhibitory receptor TIM3 is an important regu-
latory component in γδ T cell biology and may have im-
plications for disease management of malaria as well as
γδ T cell immunotherapy in general.
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Additional file 1: Figure S1. Schematic of single and multiple
infections with P. berghei and/or P. chabaudi. C57BL/6 mice were infected
with (A) P. chabaudi three consecutive times with drug treatment
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treatment and then P. berghei infection or vice versa, or (C) P. chabaudi to
establish chronic infections followed by drug treatment. (TIF 1009 kb)
Additional file 2: Figure S2. Gating strategy used to determine γδ T
cell memory populations and TIM3 expression by γδ T cells in both PBMC
samples and mice. (TIF 1730 kb)
Additional file 3: Figure S3. PD1 expression by γδ T cells is absent.
PBMCs from individuals living in malaria endemic areas and healthy
controls (HC) were surface stained for TIM3 and PD1 expression. (A)
Frequency of γδ T cells expressing TIM3 or PD1 in individuals living in
malaria endemic areas. (B) Frequency of CD3+ γδTCR– cells expressing
PD1 in HC and individuals living in malaria endemic areas. Statistical
analysis was performed using Paired t tests (A) or Mann-Whitney tests (B).
***P < 0.001. (TIF 1245 kb)
Additional file 4: Table S1. Negative binomial regression for TIM3
+ CD16+ TEMRA γδ T cell frequency and molFOI. (DOC 35 kb)
Additional file 5. Table S2. Frequency of γδ T cell responses following
background subtraction. (DOC 30 kb)
Additional file 6: Figure S4. TIM3+ γδ T cells are functionally impaired
following stimulation with iRBCs and IPP. PBMCs from individuals living in
malaria endemic areas were stimulated with either iRBCs or IPP and then
surface stained for TIM3 expression. FACS plots representing frequency of
TIM3 expression on IFN-γ, TNF-α, and CD107a producing γδ T cells following
stimulation with iRBCs and uRBCs (top panel) or IPP and no stimulation
(bottom panel). (TIF 1308 kb)
Additional file 7: Table S3. Proportional hazard model for TIM3+ CD16
+ TEMRA γδ T cell frequency and time to first clinical malaria episode.
(DOC 35 kb)
Additional file 8: Table S4. General linear model of TIM3+ γδ T cell
frequency with IL-18 levels in children with recent P. falciparum infection.
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